Cellaritybio

@cellaritybio

Founded by , Cellarity is developing medicines through an understanding of cell behaviors.

Cambridge, Massachusetts
Vrijeme pridruživanja: veljača 2019.

Tweetovi

Blokirali ste korisnika/cu @cellaritybio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @cellaritybio

  1. 7. sij
    Poništi
  2. 30. pro 2019.

    Honored that recognized Cellarity as one of a dozen companies that "exited stealth this year and made a particularly big impact."

    Poništi
  3. 23. pro 2019.

    "Can Machines Understand Complex Biology?" essay from Jordi Mata-Fink and Cellarity co-founder explores how may provide a new architecture for modern .

    Poništi
  4. 19. pro 2019.

    Karen Tkach Tuzman of took a look at how our approach "can both shine a light on the network effects of compounds with known targets, and identify compounds that influence disease networks via unknown targets."

    Poništi
  5. 18. pro 2019.

    Last week talked with the Cellarity team to capture all the details about our focus, platform and origins within .

    Poništi
  6. 17. pro 2019.

    FierceBiotech's took a deep dive into Cellarity and our platform, which unlocks the ability to study . Take a look and learn more about our approach!

    Poništi
  7. 17. pro 2019.

    Our own talks with about how an understanding of allows us to see the forest for the trees and improve the success rate of .

    Poništi
  8. 16. pro 2019.

    What if we could design medicines targeting the full cellular and molecular complexity of disease? We'd dramatically improve the success rate of drug discovery. Cellarity is pioneering a new path.

    Poništi
  9. 13. pro 2019.

    Chad Nusbaum, Ph.D., a renowned leader in developing, applying and deploying new technology to enable world-class research, has joined Cellarity as part of our leadership team. Welcome, Chad!

    Poništi
  10. 12. pro 2019.
    Poništi
  11. 12. pro 2019.

    Learn about Cellarity's approach and vantage point at

    Poništi
  12. 11. pro 2019.

    We’re delighted to introduce Cristina Rondinone, Ph.D., as our President! She joins from MedImmune-AstraZeneca, where she was Senior Vice President, Head of Cardiovascular, Renal, and Metabolic Diseases and a member of the company’s leadership team.

    Poništi
  13. 10. pro 2019.

    “For years, our team appreciated that biological processes and diseases operate at the level of networks, and they therefore explored better ways to characterize disease and discover effective drugs.” -

    Poništi
  14. 10. pro 2019.

    Today unveiled our company! The first to develop medicines targeting cell behavior by uniting network biology, AI and technology. Learn more at

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·